Open access
Open access
Powered by Google Translator Translator

Oncology – Breast

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.

20 Jan, 2022 | 08:57h | UTC

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update – Journal of Clinical Oncology

 

Commentary on Twitter

 


M-A: Beta-blockers and renin–angiotensin system inhibitors may provide a modest benefit for the preservation of left ventricular function in patients with breast cancer treated with anthracyclines or trastuzumab.

19 Jan, 2022 | 08:34h | UTC

A systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer – European Journal of Cardiology (link to abstract – $ for full-text)

Commentary: BBs, ACEI/ARBs to Prevent LV Dysfunction Due to Breast Cancer Drugs – American College of Cardiology

 


Adjuvant Capecitabine for early breast cancer: 15-year overall survival results from a randomized trial.

18 Jan, 2022 | 09:11h | UTC

Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial – Journal of Clinical Oncology

 


Final overall survival analysis of the HER2CLIMB RCT: Tucatinib vs. placebo added to Trastuzumab and Capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases.

13 Jan, 2022 | 08:12h | UTC

Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis – Annals of Oncology (link to abstract – $ for full-text)

Original Study: Randomized Trial: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

 


RCT: In patients presenting with metastatic breast cancer, early locoregional therapy for the primary site did not improve survival or quality of life.

11 Jan, 2022 | 02:29h | UTC

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


RCT: In premenopausal women with breast cancer, gonadotropin-releasing hormone analogs may preserve ovarian function against chemotherapy-induced gonadotoxic effects.

11 Jan, 2022 | 02:26h | UTC

Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Systematic Review: Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer.

9 Dec, 2021 | 10:08h | UTC

Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC) – British Journal of Cancer

 

Commentary on Twitter (thread – click for more)

 


RCT: 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.

2 Dec, 2021 | 09:49h | UTC

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Advances in Breast Cancer Radiotherapy: Implications for Current and Future Practice.

30 Nov, 2021 | 09:55h | UTC

Advances in Breast Cancer Radiotherapy: Implications for Current and Future Practice – JCO Oncology Practice

 

Commentary on Twitter

 


RCT: An exercise program reduced upper limb disability one year after non-reconstructive breast cancer surgery.

18 Nov, 2021 | 08:39h | UTC

Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): multicentre randomised controlled trial and economic evaluation – The BMJ

Commentaries:

Exercise reduces upper limb disability after breast cancer surgery – BMJ / News Medical

Exercise Helps Ease Arm, Shoulder Pain After Breast Cancer Surgery- HealthDay

Structured Exercise Improves Upper Limb Function After Breast Ca Surgery – Physician’s Weekly

 

Commentary on Twitter

 


Review: Treatment landscape of triple-negative breast cancer — expanded options, evolving needs.

16 Nov, 2021 | 08:23h | UTC

Treatment landscape of triple-negative breast cancer — expanded options, evolving needs – Nature Reviews Clinical Oncology (free for a limited period)

 

Commentary on Twitter

 


Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer.

11 Nov, 2021 | 08:32h | UTC

Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer – JCO Oncology Practice

 


Large observational study suggests prolactin-increasing antipsychotics are associated with increased risk of breast cancer (OR=1.56 for over 5 years of exposure); prolactin-sparing antipsychotics (including clozapine, quetiapine, or aripiprazole), on the other hand, were not associated with increased risk.

10 Nov, 2021 | 06:57h | UTC

Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland – The Lancet Psychiatry (link to abstract – $ for full-text)

Commentary: Choosing between antipsychotics to reduce the risk of breast cancer in women with schizophrenia – The Mental Elf

 

Commentary on Twitter

 


Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care.

9 Nov, 2021 | 01:44h | UTC

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care – European Journal of Cancer

Related:

2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients

Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging.

Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance

 


FDA Pooled Analysis: Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant.

9 Nov, 2021 | 01:05h | UTC

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT: Elective internal mammary node irradiation does not increase disease-free survival or overall survival in most women with node-positive breast cancer.

27 Oct, 2021 | 01:28h | UTC

Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial – JAMA Oncology (free for a limited period)

Commentary: No Survival Benefit for Internal Mammary Node Irradiation in Breast Cancer — Women with medially or centrally located tumors may be candidates, however, says researcher – MedPage Today (free registration required)

 

Commentary on Twitter

 


ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.

21 Oct, 2021 | 09:48h | UTC

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer – Annals of Oncology

Press release: metastatic breast cancer: new ESMO guideline with evidence-based recommendations – European Society of Medical Oncology

 


Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomized trials.

15 Oct, 2021 | 02:07h | UTC

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials – The Lancet Oncology

 

Commentary on Twitter

 


Cohort Study: Women treated with radiation therapy for left-sided breast cancer had over twice the risk of subsequent coronary artery disease compared with women treated with radiation therapy for right-sided breast cancer.

1 Oct, 2021 | 10:21h | UTC

Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer: The WECARE Study – JACC: CardioOncology

Commentaries:

Left Breast Radiation Therapy Doubles CV Disease Risk vs. Right Breast Radiation Therapy in Young Women – American College of Cardiology

CAD in Young Women After Radiation Therapy for Breast Cancer – American College of Cardiology

 

Commentary on Twitter

 


Systematic Review: Partial breast irradiation versus whole breast radiotherapy for early breast cancer.

15 Sep, 2021 | 08:46h | UTC

Partial breast irradiation versus whole breast radiotherapy for early breast cancer – Cochrane Library

 

Commentary on Twitter

 


Long-term report of study evaluating radiation following surgical excision for good-risk ductal carcinoma in situ.

14 Sep, 2021 | 08:44h | UTC

Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804 – Journal of Clinical Oncology

 

Commentary on Twitter

 


Review: neoadjuvant endocrine therapy in clinical practice.

12 Sep, 2021 | 21:34h | UTC

Neoadjuvant Endocrine Therapy in Clinical Practice: A Review – JAMA Oncology (free for a limited period)

 


Systematic review finds there is insufficient evidence that AI breast cancer screening is accurate enough to replace human scrutiny.

10 Sep, 2021 | 05:12h | UTC

Insufficient evidence that AI breast cancer screening is accurate enough to replace human scrutiny – The BMJ

Original study: Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy – The BMJ

 

Commentary on Twitter

 


Cohort study: Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers.

20 Aug, 2021 | 08:39h | UTC

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study – American Journal of Obstetrics and Gynecology

 

Commentary on Twitter

 


Oncoplastic breast surgery: A guide to good practice.

19 Aug, 2021 | 08:40h | UTC

Oncoplastic breast surgery: A guide to good practice – European Journal of Surgical Oncology

 


Stay Updated in Your Specialty

No spam, just news.